Locations:
Abu Dhabi|Canada|Florida|London|Nevada|Ohio|
Gray gradientGray gradient
Cleveland Clinic icon
Consult QD logo
Search IconSearch

Tag: neovascular age-related macular degeneration

Eye doctor looking into a man's eye

Faricimab Improves Results for Most Patients on Prior Therapy for nAMD

Switching medications may decrease treatment burden and macular fluid

22-EYE-3438365 CQD-Fluid volatility in nAMD-Ehlers

Exudative Stability Key to Anti-VEGF Outcome in nAMD

Advanced OCT features may help individualize treatment intervals

22-EYE-3141638 CQD-EYP-1901 with vorolanib for maintenance of nAMD

DAVIO Trial Results: Vorolanib Injection Reduces Treatment Burden for Patients with nAMD

53% of participants didn’t need anti-VEGF for six months or longer

21-EYE- 2468445- CQD – Faricimab in Neovascular

Effect of New Therapy Lasts Longer for Patients with Neovascular Age-Related Macular Degeneration

Faricimab every 16 weeks offers similar benefits as aflibercept every eight weeks

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

21-EYE-2172358-CQD-Rachitskaya

Even Brief Delays in Intravitreal Injection Can Cause Vision Loss

Patients with diabetic eye disease are most affected

20-EYE-1964900-Lapse-in-AMD-and-DME-treatment-Hero

Consequences of Lapse in Anti-VEGF Therapy During the COVID-19 Pandemic

Studies evaluate patients who missed treatments for diabetic macular edema and neovascular age-related macular degeneration

16-eye-2656-protocol-t-cqd-650×450

Brolucizumab Delivers Superior Elimination of Retinal Fluid and Possibly Reduced Dosing Frequency than Aflibercept in Two Studies

Greater durability of action also allows spacing of doses

BackPage 1 of 1Next

Advertisement

Ad